Ablative Solutions Stock
Ablative Solutions is a medical device firm that offers an alternative to surgical renal denervation for treating hypertension.
Sign up today and learn more about Ablative Solutions Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Ablative Solutions Stock
Ablative Solutions, Inc., was founded in 2011 by Tim Fischell, MD, FACC, and David Fischell, PhD, to address this significant unmet medical need. Ablative Solutions’ technology involves endovascular catheters to provide an efficacious, durable, cost-effective and safe alternative to surgical renal denervation for the treatment of hypertension and other diseases caused by an overactive sympathetic nervous system.
Funding History
| January 2012 | $5K |
|---|---|
| March 2012 | $3.1M |
| June 2012 | $5.3M |
| March 2013 | $8.0M |
| February 2014 | $9.6M |
| January 2015 | $14.6M |
| November 2015 | $2.5M |
| January 2019 | $77.0M |
Management
Founder
David R. Fischell
CEO & CMO, Board of Directors
Tim Fischell
President & COO, Board of Directors
Vartan Ghazarossian
Press
clinicaltrialsarena - Mar, 2 2024
Ablative's renal denervation kit hits primary endpoint in trialmassdevice - Jan, 19 2024
Ablative Solutions hits primary endpoint in renal denervation trialmassdevice - Jan, 19 2024
Gradient Denervation raises $15M Series A for catheter techmassdevice - Dec, 21 2023
Boston Scientific has more positive Farapulse datamassdevice - Dec, 21 2023
Enovis beats The Street in Q3 results, double-digit growth for ...EquityZen Recognized As:
